CCR7 and neoplasm: Patients with primary tumours that displayed high-level (‘++’ or ‘+++’) immunostaining for CCR7 had significantly worse overall and disease-specific survival rates than patients with low level (‘−’ or ‘+’) immunostaining (Figures 5 and 6, respectively).